Mood and Psychosis Symptoms during the Menopause Transition (R01 Clinical Trial Optional)
National Institutes of Health
Funding Amount
Varies
Deadline
January 7, 2028
639 days left
Grant Type
federal
Overview
Mood and Psychosis Symptoms during the Menopause Transition (R01 Clinical Trial Optional)
The purpose of this Notice of Funding Opportunity (NOFO) is to advance translational research to better understand the emergence and worsening of mood and psychotic disorders (e.g., perimenopausal depression (PMD), generalized anxiety disorder, bipolar disorder and schizophrenia) during the menopause transition (MT) in an effort to identity targets for future development of novel treatment interventions. This funding opportunity aims to advance novel and innovative translational research to better comprehend the underlying neurobiological and behavioral mechanisms of mood and psychosis disorders and related symptoms during MT. This funding opportunity also encourages interdisciplinary researchers to collaborate on studies of mood and psychosis during the MT. Aspects of mood and psychosis disorders that are of interest include: classic depressive symptoms in combination with menopause symptoms (e.g., hot flashes, night sweats, sleep disturbance) and psychological challenges, the role of reproductive steroids in the regulation of mood and behavior during the MT, diagnosis of mood and psychosis symptoms at menopausal stage, investigation of co-occurring psychiatric and menopause symptoms, appreciation of psychosocial factors common in midlife, and differential diagnoses. Review criteria will focus on the comprehensiveness of the neurobiology and mechanisms of action underlying mood and psychosis symptoms and hypothesis-driven work.
Details
- Agency: National Institutes of Health
- Department: Department of Health and Human Services
- Opportunity #: PAR-25-281
- Instrument: grant
Eligibility
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
Eligibility
Eligible Applicant Types
How to Apply
PAR-25-281 Full Announcement Text
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
<meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
<meta http-equiv="refresh" content="0; URL='http://grants.nih.gov/grants/guide/pa-files/PAR-25-281.html'" />
<title>PAR-25-281</title>
</head>
<body>
</body>
</html>
Focus Areas & Funding Uses
Fields of Work
Categories
Browse similar grants by category
Related Grants
Similar grants from this funder and related organizations
Implementing Zero Suicide in Health Systems
Substance Abuse and Mental Health Services Adminis
Amount
$0 - $700,000
Deadline
April 20, 2026
BJA FY25 Residential Substance Abuse Treatment for State Prisoners – Formula Grants Program
Bureau of Justice Assistance
Amount
$0 - $1,207,840
Deadline
April 20, 2026
Children's Mental Health Initiative
Substance Abuse and Mental Health Services Adminis
Amount
$0 - $3,000,000
Deadline
April 20, 2026
BJA FY25 Public Safety and Mental Health Initiative Training and Technical Assistance
Bureau of Justice Assistance
Amount
$0 - $3,200,000
Deadline
April 20, 2026
Assisted Outpatient Treatment Program
Substance Abuse and Mental Health Services Adminis
Amount
$0 - $750,000
Deadline
April 20, 2026
Innovation in Behavioral Health (IBH)
Center for Medicare and Medicaid Services
Amount
$0 - $7,500,000
Deadline
June 3, 2026
Ready to apply for Mood and Psychosis Symptoms during the Menopause Transition (R01 Clinical Trial Optional)?
Grantable helps you assess fit, draft narratives, and track deadlines — so you can submit stronger applications, faster.